Nevirapine hypersensitivity reaction: Will the real HLA please stand up?

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 226-230

  Hoskins, Janelle M ^a,b   Roederer, Mary W ^a,b   McLeod, Howard L ^a,b,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CYTOCHROME P450 3A4; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GENE FREQUENCY; GENETIC ASSOCIATION; HEPATITIS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; NONHUMAN; PATCH TEST; SKIN TEST; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ALLELES; DRUG HYPERSENSITIVITY; HLA ANTIGENS; HUMANS; NEVIRAPINE; RISK FACTORS;

EID: 67650236737     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (36)

1. Phillips EJ, Mallal SA: HLAs and drug-induced toxicity. Curr Opin Mol Ther (2009) 11(3):231-242
2. Martin AM, Nolan D, Gaudieri S, Phillips E, Mallal S: Pharmacogenetics of antiretroviral therapy: Genetic variation of response and toxicity. Pharmacogenomics (2004) 5(6):643-655.
3. Pollard RB, Robinson P, Dransfeld K: Safety profle of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodefciency virus infection. Clin Ther (1998) 20(6):1071-1092.
4. Viramune package insert. Revised 22 December 2003. Boehringer-Ingelheim Pharmaceuticals Inc, Ridgefeld, CT, USA (2003).
5. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defc Syndr (2004) 35(2):120-125.
6. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis (2005) 191(6):825-829.
7. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defc Syndr (2003) 34(Suppl 1):S21-S33.
8. Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, Barracchini A, De Longis P, Murri R, Tozzi V, Ammassari A et al: Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. Aids (2001) 15(12):1579-1581.
9. de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, Huitema AD, Beijnen JH: Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol (2003) 59(5-6):457-462.
10. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M et al: High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodefciency virus infection. J Infect Dis (1995) 171(3):537-545.
11. Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA: Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defc Syndr (2003) 33(1):41-46.
12. van Leth F, Andrews S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM, Montaner J: The effect of baseline CD4 cell count and HIV-1 viral load on the effcacy and safety of nevirapine or efavirenz-based frst-line HAART. Aids (2005) 19(5):463-471.
13. Dieterich DT, Robinson PA, Love J, Stern JO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis (2004) 38 (Suppl 2):S80-S89.
14. Popovic M, Caswell JL, Mannargudi B, Shenton JM, Uetrecht JP: Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chem Res Toxicol (2006) 19(9):1205-1214.
15. Liechty CA, Solberg P, Mwima G, Were W, Weidle PJ, Mermin J: Nevirapine-induced Stevens-Johnson syndrome in a mother and son. Aids (2005) 19(9):993-994.
16. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen F T, Mallal S: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Aids (2005) 19(1):97-99.
17. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 27(12):1488-1495.
18. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J: Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos (1999) 27(8):895-901.
19. Chen J, Mannargudi BM, Xu L, Uetrecht J: Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol (2008) 21(9):1862-1870.
20. Wen B, Chen Y, Fitch WL: Metabolic activation of nevirapine in human liver microsomes: Dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos (2009):doi:10.1124/ dmd.108.024851.
21. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet (2003) 361(9360):865-872.
22. Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, Hovnanian A: HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. Aids (2008) 22(4):540-541.
23. Littera R, Carcassi C, Masala A, Piano P, Serra P, Ortu F, Corso N, Casula B, La Nasa G, Contu L, Manconi PE: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Aids (2006) 20(12):1621-1626.
24. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP: Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol (2005) 18(12):1799-1813.
25. Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics (2009) 19(2):139-146.
26. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, Teruya K, Tachikawa N, Kikuchi Y, Oka S: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. Aids (2007) 21(2):264-265.
27. Middleton D, Menchaca L, Rood H, Komerofsky R: New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens (2003) 61(5):403-407.
28. Sidney J, Peters B, Frahm N, Brander C, Sette A: HLA class I supertypes: A revised and updated classifcation. BMC Immunol (2008) 9:1.
29. Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, Hewitt HS, Linde CH, Kavanagh DG, Woodberry T, Henry LM et al: Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 37(9):2419-2433.
30. Saito S, Ota S, Yamada E, Inoko H, Ota M: Allele frequencies and haplotypic associations defned by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens (2000) 56(6):522-529.
31. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME: Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut (1995) 36(2):259-267.
32. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Roland Wolf C: Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem (2003) 316(1):103-110.
33. Dooley TP, Haldeman-Cahill R, Joiner J, Wilborn TW: Expression profling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells. Biochem Biophys Res Commun (2000) 277(1):236-245.
34. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA: Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. Aids (2005) 19(2):185-192.
35. Wood R: Nevirapine toxicity - implications for management of South African patients. S Afr Med J (2005) 95(4):253-257.
36. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P et al HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 358(6):568-579.